|
Mayo Clinic DILI implementation |
Drug Induced Liver Injury |
Mayo Clinic |
Case, Control |
|
|
16%, 100% |
|
|
Height Implementation - Columbia |
Height |
Columbia University |
Case Only |
|
|
|
|
|
CHOP_T2D |
Type 2 Diabetes - PRS Evaluation |
CHOP |
Case, Control |
|
|
|
|
|
RBC Implementation - Columbia |
Red Blood Cell Indices |
Columbia University |
Case Only |
|
|
|
|
|
VUMC_T1DM |
Type 1 Diabetes |
VUMC |
Case, Control |
|
|
|
|
|
CCHMC Primary Validation |
Migraine |
|
Case Only |
|
|
92% |
|
|
CHOP Pneumonia |
Pneumonia- VUMC eMERGE v5.1 |
CHOP |
Case, Control |
|
|
|
|
|
Mayo CAAD cases and controls |
CAAD (Carotid Artery Atherosclerosis Disease) |
Mayo |
Case, Control |
13 |
|
100% |
71% |
|
Diverticulosis May 2012 Implementation |
Diverticulosis and Diverticulitis |
Northwestern University The Feinberg School of Medicine |
Case, Control |
|
|
98%, 89% |
99%, 98% |
|
Marshfield SLE Implementation |
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria |
Marshfield Clinic Research Institute |
Case Only |
|
|
|
|
|
Mayo SLE Implementation |
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria |
Mayo Clinic |
Case, Control |
0 |
0 |
|
|
|
CHOP Post-event Pain |
Post-event Pain algorithm |
CHOP |
Case, Control |
99 |
2 |
96% |
|
|
Early Childhood Obesity Implementation - Columbia |
Severe Early Childhood Obesity |
Columbia University |
Case, Control |
2 |
3 |
|
|
|
Marshfield Zoster implementation |
Herpes Zoster |
Marshfield Clinic Research Foundation |
Case, Control |
10 |
10 |
100%, 100% |
|
|
Validation of Asthma algorithm - Geisinger |
Asthma |
Geisinger |
Case, Control |
10 |
10 |
100%, 100% |
|
|
Marshfield C-diff implementation |
Clostridium Difficile Colitis |
Marshfield Clinic Research Foundation |
Case, Control |
21 |
10 |
100%, 100% |
|
|
Appendicitis Case 1, Control |
Appendicitis |
Cincinnati Children's Hospital Medical Center |
Case, Control |
15 |
20 |
93%, 100% |
|
|
Geisinger c.Diff eMERGE3 Implementation |
Clostridium Difficile Colitis |
Geisinger |
Case, Control |
20 |
20 |
100%, 100% |
100%, 100% |
|
Marshfield AAA implementation |
Abdominal Aortic Aneurysm ( AAA ) |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
22 |
100%, 100% |
|
|
Group Health and UW Zoster Implementation |
Herpes Zoster |
Group Health and UW |
Case, Control |
25 |
25 |
100%, 96% |
100% |
|
Marshfield Hearing loss validation |
Hearing Loss |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 100% |
|
|
Group Health/University of Washington CRC Validation |
Colorectal Cancer (CRC) |
GH/UW |
Case, Control |
25 |
25 |
92%, 100% |
100%, 100% |
|
Statin and MACE Mount Sinai Implementation |
Statins and MACE |
Mount Sinai |
Case Only |
52 |
25 |
96%, 100% |
100%, 100% |
|
Implementation For Phase 3 eMERGE |
Electronic Health Record-based Phenotyping Algorithm for Familial Hypercholesterolemia |
Geisinger |
Case, Control |
25 |
25 |
100%, 96% |
|
|
Marshfield ACE-I cough implentation |
ACE Inhibitor (ACE-I) induced cough |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 96% |
|
